mdlinx mdlinx
Latest (64) Full Text Articles (1329) Article Summary

Budesonide/Formoterol Maintenance and Reliever Therapy in Asian Patients (Aged ≥16 Years) with Asthma: A Sub-Analysis of the COSMOS Study
Clinical Drug Investigation,  Clinical Article

Vogelmeier C et al. – In patients (aged ≥16 years) enrolled from Asian countries as part of the COSMOS study, the budesonide/formoterol maintenance and reliever regimen was associated with a lower future risk of exacerbations versus the physicians' free choice of salmeterol/fluticasone propionate dose plus salbutamol. Single inhaler combination treatment with maintenance plus as–needed budesonide/formoterol was also at least as efficacious as salmeterol/fluticasone propionate dose plus salbutamol in improving current asthma control.

Methods
  • This sub–analysis of the COSMOS study concerns all 404 randomized patients ≥16 years of age (mean forced expiratory volume in 1 second [FEV1] 69.1%) who were recruited from Asian countries.
  • Patients received either budesonide/formoterol (Symbicort Turbuhaler SMART, n=198), starting dose 160 mg/4.5 mg two inhalations twice daily (bid) [plus additional as–needed inhalations], or salmeterol/fluticasone propionate (Seretide Diskus, n=206), starting dose 50 mg/250 mg bid (plus salbutamol [Ventolin] as needed).
  • Maintenance doses could be titrated by clinicians after the first 4 weeks (budesonide/formoterol maintenance plus as needed, n=198; salmeterol/fluticasone propionate plus salbutamol, n=206).
  • To allow for free adjustment in maintenance doses in both arms, the trial was performed open–label; maintenance doses could be titrated by clinicians after the first 4 weeks.
  • The time to first severe exacerbation (defined as deterioration in asthma resulting in hospitalization/emergency room treatment, oral corticosteroids for ≥3 days or unscheduled visit leading to treatment change) was the primary variable.

Results
  • The time to first severe exacerbation was prolonged in patients using maintenance plus as–needed budesonide/formoterol compared with salmeterol/fluticasone propionate plus salbutamol (log–rank p=0.024).
  • The risk of a first exacerbation was reduced by 44% (hazard ratio 0.56; 95% confidence interval [CI] 0.32, 0.95; p=0.033) in patients using the adjusted budesonide/formoterol regimen versus titrated salmeterol/fluticasone propionate.
  • The overall exacerbation rates were 0.16 versus 0.26 events/patient–year, respectively, with a 38% reduction (rate ratio 0.62/patient/year; 95% CI 0.41, 0.94; p=0.024) in favour of the budesonide/formoterol regimen.
  • Compared with baseline, both regimens provided clinically relevant improvements in asthma control, quality of life and FEV1; no statistically significant differences between the treatment groups were observed.
  • Mean adjusted (standard deviation) ICS dose (expressed as beclomethasone dose equivalents) during treatment, including as–needed budesonide doses, was 944 (281) and 1034 (394) μg/day, respectively, in patients using maintenance plus as–needed budesonide/formoterol compared with salmeterol/fluticasone propionate.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

Last month's top read Top Articles of 2013

1 Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy Clinical Infectious Diseases, January 30, 2014    Clinical Article

2 Prescribing of high-dose acetaminophen products discouraged Full Text U.S. Pharmacist, March 11, 2014    Free full text    Clinical Article

3 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

4 New antiviral agents for the treatment of hepatitis C: ABT-450 Expert Opinion on Pharmacotherapy, March 19, 2014    Review Article
Exclusive Author Commentary

5 Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: Clinical and economic consequences PharmacoEconomics, February 11, 2014    Clinical Article

6 Collaborative practice model between cardiologists and clinical pharmacists for management of patients with cardiovascular disease in an outpatient clinic Annals of Pharmacotherapy, March 5, 2014    Review Article

7 A waste walk through clinical pharmacy: How do the seven wastes of Lean techniques apply to the practice of clinical pharmacists International Journal of Pharmacy Practice, March 27, 2014    Clinical Article

8 Effect of chronic statin treatment on vascular remodeling determined by intravascular ultrasound in patients with acute myocardial infarction The American Journal of Cardiology, March 7, 2014    Clinical Article

9 Agomelatine: A new option for treatment of depression? Expert Opinion on Pharmacotherapy, February 13, 2014    Clinical Article

10 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

11 The cardiotoxicity of cancer-related drug therapies Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

12 How long does a flu shot last? The New York Times, January 20, 2014

13 Care transitions in elderly heart failure patients: Current practices and the pharmacists role The Consultant Pharmacist, March 6, 2014    Review Article

14 The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint Nutrition, Metabolism & Cardiovascular Diseases, March 7, 2014    Clinical Article

15 Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria Journal of Clinical Pharmacy and Therapeutics, March 6, 2014    Clinical Article

16 Pediatric hypertension Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

17 Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review British Journal of Clinical Pharmacology, February 13, 2014    Evidence Based Medicine    Review Article

18 Antidepressant use and risk of coronary heart disease: Meta-analysis of observational studies British Journal of Clinical Pharmacology, March 21, 2014    Evidence Based Medicine

19 National trends in prescription drug expenditures and projections for 2014 American Journal of Health-System Pharmacy, March 4, 2014    Clinical Article

20 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Other Topics in Pharmacy

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close